Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Welcome and Introduction to Vi3C

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Jan
11
Today In Oncology
Flipped Nivolumab/Ipilimumab Dosing Improves Outcomes in Advanced Melanoma
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Researchers Create Immune Cell Atlas of Bone Marrow in Patients With Multiple Myeloma
Small Study Examines Potential of Artificial Saliva in Patients With Head and Neck Cancer
Are Food Preservatives Linked to Increased Cancer Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo